Ginkgo Bioworks Holdings, Inc.
DNA
$7.54
-$0.27-3.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 227.04M | 217.95M | 184.34M | 208.70M | 251.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 227.04M | 217.95M | 184.34M | 208.70M | 251.46M |
| Cost of Revenue | 44.55M | 41.54M | 36.46M | 40.83M | 54.01M |
| Gross Profit | 182.50M | 176.41M | 147.88M | 167.87M | 197.45M |
| SG&A Expenses | 236.34M | 249.43M | 279.17M | 307.52M | 348.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 766.00K | 766.00K | 766.00K | -3.22M | -3.22M |
| Total Operating Expenses | 705.71M | 756.46M | 860.77M | 899.57M | 980.07M |
| Operating Income | -478.67M | -538.50M | -676.43M | -690.87M | -728.62M |
| Income Before Tax | -547.51M | -651.54M | -897.68M | -853.93M | -892.94M |
| Income Tax Expenses | -479.00K | -352.00K | 1.00K | -122.00K | -71.00K |
| Earnings from Continuing Operations | -547.03 | -651.19 | -897.68 | -853.81 | -892.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -547.03M | -651.19M | -897.68M | -853.81M | -892.87M |
| EBIT | -478.67M | -538.50M | -676.43M | -690.87M | -728.62M |
| EBITDA | -415.65M | -478.30M | -612.34M | -626.45M | -658.11M |
| EPS Basic | -10.62 | -12.90 | -18.03 | -17.39 | -18.36 |
| Normalized Basic EPS | -5.22 | -5.94 | -7.64 | -7.99 | -8.54 |
| EPS Diluted | -10.63 | -12.92 | -18.05 | -17.41 | -18.39 |
| Normalized Diluted EPS | -5.22 | -5.93 | -7.64 | -7.98 | -8.54 |
| Average Basic Shares Outstanding | 207.54M | 203.16M | 199.69M | 196.66M | 194.42M |
| Average Diluted Shares Outstanding | 207.57M | 203.23M | 199.75M | 196.71M | 194.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
